Is Repligen (RGEN) Pricing Look Attractive After Steep Multi Year Share Price Declines

• Wondering whether Repligen's share price reflects its true worth, or if the market is missing something important about this stock's value today.
• Repligen closed at US$111.49 with share price returns of a 4.2% decline over the past week, a 13.4% decline over the past month, a 32.2% decline year to date, a 12.4% decline over 1 year, a 31.8% decline over 3 years, and a 44.4% decline over 5 years, which may have some investors reassessing both risk and potential reward.
• Recent coverage has focused on Repligen's position within the life sciences tools space and how sentiment toward the sector has shifted, with investors paying close attention to balance sheet strength and capital allocation choices. Together, these themes help frame why the share price is where it is today and why opinions on future prospects may be split.
• Repligen currently has a valuation score of 3 out of 6. The next sections will compare what different valuation methods say about the stock and then finish with a broader way to think about value beyond the headline numbers.

Find out why Repligen's -12.4% return over the last year is lagging behind its peers.

Approach 1: Repligen Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model projects the cash a company could generate in the future and then discounts those cash flows back to today to estimate what the business might be worth in $ right now.

For Repligen, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $81.5 million. Analyst estimates and subsequent extrapolations by Simply Wall St project free cash flow reaching $364.7 million by 2030, with intermediate years such as 2026 to 2029 expected in a range between $120.5 million and $272.5 million based on the provided projections.

When all projected cash flows are discounted back to today, the DCF model arrives at an estimated intrinsic value of about $161.62 per share. Compared with the recent share price of $111.49, this implies Repligen trades at an intrinsic discount of around 31.0%, which indicates that, on this cash flow view, the shares appear inexpensive.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Repligen is undervalued by 31.0%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Repligen.

Approach 2: Repligen Price vs Earnings

For profitable companies, the P/E ratio is a straightforward way to link what you pay for a share with the earnings that support that price. It gives you a quick sense of how much the market is willing to pay for each dollar of current earnings.

What counts as a “normal” P/E depends on how the market views growth potential and risk. Higher expected earnings growth or lower perceived risk can support a higher P/E, while slower growth or higher risk usually points to a lower, more conservative multiple.

Repligen currently trades on a P/E of 128.45x. That is well above the Life Sciences industry average of 29.81x and also higher than the peer group average of 35.63x. Simply Wall St’s Fair Ratio for Repligen is 25.54x, which is a proprietary estimate of an appropriate P/E based on factors such as earnings growth, industry, profit margins, market cap and company specific risks.

The Fair Ratio adds context that simple industry or peer comparisons miss, because it adjusts for Repligen’s own characteristics rather than assuming it should match an average. Comparing 128.45x with the Fair Ratio of 25.54x suggests the shares trade at a richer multiple than this framework would imply.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose Your Repligen Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as a simple way for you to attach a clear story about Repligen to the numbers you care about, linking your view on its future revenue, earnings and margins to a Fair Value that can be compared with today’s price.

On Simply Wall St’s Community page, Narratives let you set or adopt a forecast and Fair Value, then see at a glance whether that Fair Value sits above or below the current Repligen share price. This can help you decide whether the stock appears attractive or stretched based on your own assumptions rather than anyone else’s.

Because Narratives update automatically when new earnings, news or guidance arrive, your Repligen view stays current without manual rework. You can immediately see how fresh information affects both the story and the valuation that follows from it.

For example, one Repligen Narrative might align with the most optimistic analyst view that supports a Fair Value of about US$220.00 per share, while another might echo the most cautious stance closer to US$131.29. By choosing which story you find more realistic, you effectively choose which Fair Value you want to use in your own decision making.

Do you think there's more to the story for Repligen? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com